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Telomeric chromosome rearrangements may cause mental retardation, congenital anomalies, and miscarriages.
Automated detection of subtle deletions or duplications involving telomeres is essential for high-throughput di-
agnosis, but impossible when conventional cytogenetic methods are used. Array-based comparative genomic hy-
bridization (CGH) allows high-resolution screening of copy number abnormalities by hybridizing differentially
labeled test and reference genomes to arrays of robotically spotted clones. To assess the applicability of this technique
in the diagnosis of (sub)telomeric imbalances, we here describe a blinded study, in which DNA from 20 patients
with known cytogenetic abnormalities involving one or more telomeres was hybridized to an array containing a
validated set of human-chromosome–specific (sub)telomere probes. Single-copy-number gains and losses were ac-
curately detected on these arrays, and an excellent concordance between the original cytogenetic diagnosis and the
array-based CGH diagnosis was obtained by use of a single hybridization. In addition to the previously identified
cytogenetic changes, array-based CGH revealed additional telomere rearrangements in 3 of the 20 patients studied.
The robustness and simplicity of this array-based telomere copy-number screening make it highly suited for intro-
duction into the clinic as a rapid and sensitive automated diagnostic procedure.
Introduction
Genomic imbalances can cause mental retardation, con-
genital malformations and miscarriages. The best known
example of a genetic imbalance compatible with life is
Down syndrome, which is caused by trisomy of chro-
mosome 21 and is present in 1 of 700 newborn children.
Relatively small genomic deletions or duplications may
also result in clinical phenotypes. Well-known micro-
deletion syndromes include the Williams (7q11.2), Pra-
der Willi (15q12), Angelman (15q12), Wolf-Hirschhorn
(4p16.3), and DiGeorge (22q11.21) syndromes (Battaglia
and Carey 1998; Cassidy et al. 2000; Donnai and Kar-
miloff-Smith 2000; Scambler 2000). In recent years, the
development and application of various subtelomeric
probes for FISH and microsatellite markers from these
regions, led to the awareness that (sub)telomeric regions
are often involved in chromosomal rearrangements not
visible by routine cytogenetics. These submicroscopic sub-
telomeric chromosome rearrangements are a significant
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cause of mental retardation with or without congenital
anomalies (Flint et al. 1995; Knight et al. 1999; de Vries
et al. 2000; Knight and Flint 2000).
The development of an accurate and sensitive method
of screening all subtelomeric regions can facilitate the
clinical diagnosis of a considerable group of patients.
FISH-based approaches, which are currently employed
in the majority of diagnostic centers, are hampered by
the need for high-quality metaphase spreads and the
limited number of chromosomal loci that can be
screened in a single reaction. Array-based comparative
genomic hybridization (CGH), the application of CGH
to an array of mapped DNA fragments immobilized on
glass slides (Solinas-Toldo et al. 1997; Pinkel et al. 1998;
Snijders et al. 2001), is rapidly becoming the method
of choice for high-resolution screening of genomic copy-
number changes (Antonarakis 2001). Array-basedCGH
builds upon previously well-established CGH proce-
dures (Kallioniemi et al. 1992; Weiss et al. 1999; Lichter
et al. 2000) by use of differentially labeled test (patient)
and reference (normal) DNAs, to be cohybridized, un-
der in situ suppression hybridization conditions, to
cloned genomic fragments in a miniaturized (arrayed)
format on a chip. The hybridized DNAs are detected in
two different fluorochromes and digitized intensity dif-
ferences in the hybridization patterns of the DNAs onto
these cloned fragments can be interpreted as copy-num-
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Table 1
Patients, Reasons for Referral, Karyotypes, and Array-Based CGH Results, Including Comparisons with the Original Karyotypes
Patient
Reason for
Referrala Karyotype Array-Based CGH Array-Based CGH vs. Karyotype
2 MCA 46,XY,del(18)(q21.2) Loss 18qterb Match
3 MCA/MR 46,XX,del(18)(p11.2) Loss 18pter Match
4 MCA/MR 46,XX,del(10)(q26.1) Loss 10qter Match
5 MCA/MR 46,XX,der(3)t(3;16)(p25;q22) Loss 3pter, gain 16qter Match
7 MCA/MR 46,XY,del(10)(q26.13) Loss 10qter Match
9 PD 46,X,del(X)(p22.1) Loss XpYpter Match
10 MCA/MR 46,XY,del(7)(q36) Loss 7qter Match
11 MR 46,XY,der(21)t(21;22)(p10;q13.3) Gain 22qter Match
12 MR 46,XY,der(2)t(2;?)(q37.3;?)c Loss 2qter Match
15 MR 46,XX,del(2)(q37.3) Loss 2qter Match
16 MCA 46,XX,der(20)t(20;?)(q13.3;p?)d Loss 20qter Match
17 MR 46,XX,del(13)(q33) Loss 13qter Match
20 Turner syndrome 46,XX,del(11)(q23.3) Loss 11qter Match
1 MCA 46,XY,del(9)(p22p24.2) Normal Match (interstitial deletion)
19 MR 46,XY,del(3)(q27.3q29) Normal Match (interstitial deletion)
6 MCA 46,XY,del(13)(q32.2) Normal FISH:13qter normal, deletion interstitial
13 Down syndrome 46,XX,add(2)(q36.2) Normal Chromosome CGH: 2qter normal, gain of 8q24; in-
sertion interstitial
8 MCA/MR 45,XY,der(13;14)(q10;q10),
dup(17)(qterq24.2)
Gain 17qter and loss
17qter
FISH: gain and loss confirmed, inversion
duplication followed by deletion of distal part
17qter
14 MCA 46,XX,der(9)t(9;?)(p24;?) Loss 9pter and gain
7pter
FISH: gain of 7pter confirmed, translocation partner
identified
18 MCA 46,XY,dup(8)(p23p12) Loss 8pter FISH: loss of 8pter confirmed, inversion duplication
followed by deletion distal part of 8pter
a MCA p multiple congenital abnormalities; MR p mental retardation; PD p prenatal diagnosis (delXp22.1 present in parent).
b The pter and qter clones from the second second-generation set of human-chromosome–specific (sub)telomere probes (Knight et al. 2000).
c Satellite at chromosome 2.
d Satellite at chromosome 20.
ber differences between the test and reference genomes.
This technique, once established and validated, will al-
low high-throughput “cytogenetic” diagnosis (molec-
ular karyotyping) with a theoretically unlimited reso-
lution. It has already been shown to be useful in rapid
amplicon identification (Albertson et al. 2000), differ-
ential tumor diagnosis (Wilhelm et al. 2002), and the
biological dissection of the role that copy-number
changes play in different tumor types (Bruder et al.
2001). The primary purpose of this study was to test
the feasibility of array-based CGH for copy-number
screening of subtelomeric regions in patients with men-
tal retardation with or without congenital anomalies.
A previously published second-generation set of hu-
man-chromosome–specific (sub)telomeric probes (Knight
et al. 2000) was used as target for array-based CGH. A
blinded study with 20 cytogenetically well-characterized
patient samples was performed on these arrays together
with a number of normal-versus-normal control and
other reproducibility experiments. FISH validation was
performed in those patients in which discrepancies be-
tween array-based CGH and the conventional cytoge-
netic analysis were observed. Furthermore, we tested the
use of degenerate oligonucleotide-primed PCR (DOP-
PCR) (Telenius et al. 1992) protocols for the generation
of large amounts of clone DNA and compared the per-
formance of array-based CGH on DOP-PCR products
with that of array-based CGH on primary clone DNAs.
Patients, Material, and Methods
Patients
A series of 18 patients was selected from our Clinical
Genetics patient database on the basis of microscopic
chromosomal rearrangements involving at least one sub-
telomeric region (table 1). In addition, two patients (1
and 19) with an interstitial deletion were included as
negative controls (the study was performed in a blinded
fashion). In most patients, a direct and accurate cyto-
genetic diagnosis was possible. In two patients (13 and
14), however, an unambiguous karyotype could not be
established because of the limited resolution of the
banded chromosomes. Karyotypes from all patients, to-
gether with previously performed FISH analyses, were
re-evaluated, and the abnormalities were confirmed. All
cytogenetic diagnoses were performed on direct cultures
of patient material. Peripheral blood lymphocytes from
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each patient were Epstein-Barr–virus–transformed, and
genomic DNAs were isolated from short-term cultures
by use of standard procedures. This DNA was used for
array-based CGH, as well as FISH and, in one patient,
chromosomal CGH. DNAs isolated from blood lym-
phocytes from cytogenetically normal healthy persons
were used as references in the CGH experiments.
Clones
Part of the second-generation set of human-chromo-
some–specific (sub)telomere probes (Knight et al. 2000)
was kindly supplied by Drs. Regina Regan and Jonathan
Flint (Institute of Molecular Medicine, John Radcliffe
Hospital, Oxford, United Kingdom). The remaining
clones were commercially obtained (Incyte Genomics
and Invitrogen). In addition to the 77 clones from this
second-generation set, 3 cosmid clones from the first-
generation set were added (Ning et al. 1996). All clones
( ) were colony purified prior to culturing. Ge-np 80
nomic target DNAs were isolated from 200-ml bacterial
cultures by use of QIAgen Plasmid Midi Kits (QIAgen),
according to the manufacturer’s instructions. All clones
were PCR verified by use of the STSs developed by
Knight et al. (2000), and their mapping positions were
confirmed by FISH on normal metaphase spreads by use
of routine procedures. DNA from a total of 77 clones
passed STS verification and mapped to the correct tel-
omere location. The three clones that did not pass this
test were GS-240-G10 (16q), GS-48-O23 (19q), and GS-
202-M24 (Xq). DNAs from these clones were subse-
quently used in the array-based CGH experiments. All
of the 41 human subtelomeric chromosome regionswere
represented, by either one (9 regions), two (29 regions),
or three (3 regions) clones.
Array-Based CGH
DNAs from all clones were sonicated to generate frag-
ments 300–3,000 bp in size and were dissolved at a
concentration of 1 mg/ml in a 80% dimethyl sulfoxide
solution containing 0.3 mg/ml nitrocellulose. The clone
DNAs were robotically spotted in triplicate onto glass
slides coated with Corning Microarray Technology
gamma amino propyl citrate (Corning) by use of an Af-
fymetrix 417 arrayer. The center-to-center spacing of the
spots was 250 mm, and the size of the array was 1.44
cm2. Slides were air dried overnight and DNA was ul-
traviolet crosslinked at 90 mJ by use of a Stratalinker
(Stratagene). DNA samples were coded, and an inves-
tigator, without knowledge of the cytogenetic diagno-
sis, performed the array-based CGH analysis. Genomic
DNA, from test and reference samples, was also soni-
cated to generate fragments 300–3,000 bp in size. This
DNA was labeled by random priming in a total volume
of 80 ml. For this labeling, 500 ng DNA was mixed with
50 mM Tris-HCl (pH 6.8), 5 mM MgCl2, 10 mM 2-
mercaptoethanol, and 300 mg/ml random octamers (Bio-
prime DNA labeling system; 1# Random Primers so-
lution, Invitrogen) and was denatured at 100C for 10
min. After cooling to 4C, 64 U Klenow fragment (Bio-
prime DNA labeling system, Invitrogen), 2 mM dGTP,
2 mM dCTP, 2 mM dATP, 1 mM dTTP (Invitrogen),
and 6 nmol fluorolink Cy3-dUTP (test) or Cy5-dUTP
(reference) (Amersham Pharmacia Biotech) were added.
This solution was incubated for 2 h at 37C, after which
unincorporated fluorescent nucleotides were removed by
use of Sephadex G-50 spin columns (Amersham Phar-
macia Biotech). Test and reference samples were mixed
with 100 mg Cot-1 DNA (Invitrogen), were coprecipi-
tated, and were resuspended in 15 ml of a hybridization
solution containing 50% formamide, 10% dextran sul-
fate, 2# saline sodium citrate (SSC), 4% SDS and 100
mg yeast tRNA (Invitrogen). The hybridization solution
was denatured for 10 min at 72C and subsequently was
incubated for 30 min at 37C, to allow blocking of re-
petitive sequences. Subsequent hybridization was per-
formed at 37C under a sealed coverslip for 48 h by use
of an Omnislide thermal cycling block (Thermo Hy-
baid). This was followed by a 15-min posthybridization
wash in 50% formamide/2# SSC at 45C, and a 10-
min wash in phosphate buffer at room temperature, both
by use of the Omnislide heated wash module (Thermo
Hybaid). Slides were dried, after a brief ethanol wash,
and were imaged on an Affymetrix 428 scanner (Affym-
etrix) by use of the Affymetrix 428 scanner software
package (version 1.0).
Image Analysis and Processing
The acquired microarray images were analyzed by use
of Genepix Pro 3.0 (Axon Instruments). DNA spotswere
automatically segmented, local background was sub-
tracted, and total intensities—as well as the fluorescence-
intensity ratios of the two dyes—were calculated for each
spot. For all calculations, we used the median of the
pixel-by-pixel ratios of the pixel intensities that have had
the median local background intensity subtracted. Spots
with poor-quality printing and/or hybridization (indi-
cated in Genepix Pro 3.0 by “Rgn R2 !0.5”), spots with
a low signal intensity (indicated in Genepix Pro 3.0
by “%1B6352SD!30” for the Cy5 channel and
“%1B5322SD!30” for the Cy3 channel), and spots
showing autofluorescent particles over the target DNAs
were discarded. The mean test-over-reference (T/R) ratio
of the triplicate of each clone was calculated and was
divided by the median T/R ratio of all targets present
on the array, to center the ratios to 1.0. We edited the
data files to remove ratios both on clones for which the
SD of the triplicates was 120% and on clones for which
only one of the triplicates passed the inclusion criteria.
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For all array hybridizations included in this study, 88%
of the clones passed these criteria and were, therefore,
included in the final analysis. The average SD for the
triplicates was 5%.
Normal clone-to-clone variation in fluorescence-in-
tensity ratios was measured in five normal-versus-nor-
mal experiments, by averaging the ratios obtained for
each clone and calculating the SD from this average.
These control experiments represent an important qual-
ity measurement of possible label-related problems and
allow a good estimate of slide-to-slide variation. The
average ratio of each clone in the five experiments varied
between 0.94 and 1.17 (mean 1.0, as a result of the
centering step described above). This intrinsic clone-to-
clone variability was corrected in the analysis of the
patients’ DNAs by division of each intensity ratio by the
mean intensity ratio of that particular clone in the nor-
mal-versus-normal hybridizations. The SD in these five
control experiments ranged from 0.01 to 0.14, with a
mean of 0.05. One clone (GS-963K6, located on 4qter)
showed a SD 10.1, and this clone was excluded from
further analyses. On basis of these experiments, we de-
cided that a safe normal range would be 0.8–1.2, a range
that is broader than calculated on basis of two times the
SD for each clone calculated in the normal-versus-nor-
mal hybridizations.
DOP-PCR
From each clone, DNA was amplified using routine
DOP-PCR protocols (Telenius et al. 1992). In brief,
PCRs were performed in a total volume of 100 ml 1#
PCR buffer, containing 50 ng template DNA, 5 U Taq
DNA polymerase, 200 mM dNTPs, 3 mM MgCl2, and
1.5 mM of DOP primer (5′-CCG ACT CGA GNNNNN
NAT GTG G-3′) (Invitrogen). Samples were processed
in a 96-well reaction plate at 94C for 3 min, followed
by 30 cycles of 95C for 30 s, 37C for 30 s, a linear
ramp from 37C to 72C over 10 min, and 72C for 1
min, followed by a final extension at 72C for 10 min.
All reactions were performed in a PCR Express machine
(Thermo Hybaid). DOP-PCR products were purified us-
ing the QIAquick filter system (QIAgen) and were dis-
solved in 70 ml water. These PCR products were pro-
cessed in exactly the same manner as described above
for primary clone DNAs. Arrays were constructed con-
taining both primary DNAs and DOP-PCR products
from the entire subtelomeric clone set.
FISH and Chromosomal CGH Validation Experiments
FISH validation experiments were performed onmeta-
phase spreads prepared from patient-derived cell lines
by use of routine procedures. Probe labeling, slide prep-
aration, and hybridization were performed essentially as
described elsewhere (de Bruijn et al. 2001). CGH anal-
ysis was performed for validation of one patient, as de-
scribed by Simons et al. (1999). A Zeiss epifluorescence
microscope equipped with appropriate filters was used
for visual examination of the slides. Digital images were
captured by use of a high-performance cooled CCD cam-
era (Photometrics) coupled to a Macintosh Quadra 950
computer. The Image FISH software package (Intergen)
was used for analysis of the FISH images. Inverted im-
ages of slides stained with 4′,6-diamino-2-phenylindole
were used for chromosome identification. Examination
of the CGH images was performed by use of the Quips
CGH analysis software (Vysis).
Results
Our subtelomeric array contained whole clone DNAs
isolated from a second-generation set of 77 subtelomeric
genomic fragments cloned into PACs, P1s or BACs, con-
firmed to be located within 500 kb of all human telo-
meres (Knight et al. 2000). The applicability of array-
based CGH in detecting subtelomeric copy-number
changes was tested in a blinded fashion by hybridizing
total genomic DNAs from 20 cytogenetically preselected
patients to this array in the presence of normal reference
DNA. The subtelomeric copy-number profile of these
patients was analyzed through fluorescence ratios indi-
cating copy-number gains or losses, and the results were
compared with the original diagnoses based on routine
karyotyping (fig. 1 and table 1). Thresholds for copy-
number gain (1.2) and loss (0.8) were set on the basis
of five normal-versus-normal control experiments (see
the “Material and Methods” section).
In 16 patients, specific subtelomeric regions (repre-
sented by either one, two, or three clones) showing
copy-number gains (mean 1.28) or losses (mean 0.67)
could be identified, whereas, in four patients, no fluo-
rescence ratios crossed the thresholds for copy-num-
ber gain or loss. As a representative example, figure 1A
shows the array-based CGH profile of patient 2 (kar-
yotype: 46,XY,del[18][q21.2]). Both clones mapping to
the subtelomere of 18q exhibit intensity ratios !0.8, the
threshold for copy-number loss. Equally important is
the observation that the fluorescence ratios of the other
subtelomeric clones are nicely distributed within the
normal range. Comparison of the overall array-based
CGH diagnoses with the original cytogenetic diagnoses
showed a perfect match in 15 patients and disparities
in 5 patients. These latter patients are individually de-
scribed below (see also fig. 1 and table 1).
The array-based CGH profile of patient 6 (karyotype:
46,XY,del[13][q32.2]) did not confirm the cytogenetic
finding in two independent hybridizations to the telo-
meric array, although this aberration (i.e., loss of the
distal part of the long arm of chromosome 13) had been
interpreted as a terminal deletion, on the basis of high-
Figure 1 Telomere screening by array-based CGH. A–C, Telomere profiles of three patients. The arrays were composed of 77 cloned
subtelomeric genomic DNA targets, ordered within each chromosome from pter to qter. Results for clone GS-963-K6, located on 4qter, are not
included because of the high variability observed in the normal-versus-normal hybridizations (see the “Material and Methods” section). The
unblackened squares represent the T/R values of the control hybridizations, individually normalized to a value of 1. The vertical lines represent
twice the SD for each target clone in the control hybridizations. Next to that, the dark horizontal lines indicate the thresholds for copy-number
loss (0.8) and gain (1.2). The blackened squares represent the normalized T/R ratios for patient 2 (46,XY,del[18][q21.2]) (A), patient 8
(46,XY,der[13;14][q10;q10],dup[17][qterq24.2]) (fig. 1B) and patient 14 (46,XX,der[9]t [9;?)[p24;?]) (fig. 1C) versus reference hybridization.
A shows a clear loss of both telomeric targets mapping to the subtelomeric region of the long arm of chromosome 18. In B, gain of one 17qter
clone and deletion of the other 17qter clone is observed in patient 8. In C, gain of the 7pter clone and loss of both 9pter clones is observed.
D, Quadruplicate array-based CGH experiment of patient 10 (46,XY,del[7][q36]). The unblackened squares represent the mean T/R values
obtained with the DOP-PCR products, and the blackened squares represent the mean T/R values obtained with the whole clone DNAs as
targets. The vertical lines represent the SD for each target clone in the four hybridizations. The deletion of the distal part of the long arm of
chromosome 7 is clearly identified in the whole clone DNAs and, to a lesser extent, in the DOP-PCR products (in one experiment, the T/R
value for this clone was 0.87). In addition, the SDs of the DOP-PCR products of two clones, GS-1011-O17 on 2qter and GS-546-C11 on
19pter, crossed the threshold for copy-number gain because of a false-positive result in one of the four repeat experiments. E and F, FISH
validation experiments of patient 8. The duplicated 17qter clone is labeled in green; the deleted 17qter clone is labeled in red. The duplication
is visible in interphase (F), and the deletion is visible in both interphase (F) and metaphase (E). G and H, FISH validation experiments of patient
14 (Gmetaphase,H interphase). The 7pter clone is labeled in green, and chromosome 7 centromere is labeled in red for chromosome identification.
The 7pter clone is present on both chromosome 7 homologs, as well as on the short arm of chromosome 9, thus confirming the unbalanced
translocation as identified by array-based CGH.
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resolution chromosome studies. FISH on metaphase
chromosomes was performed with both 13qter clones
present on the array and with clone RP11-235O20 lo-
cated at 13q32.2. The deletion at 13q32.2 could indeed
be identified by use of this latter clone as a probe. In
contrast, both 13qter clones were present on the normal
chromosome 13, as well as on the chromosome 13 con-
taining the 13q32.2 deletion, in all metaphases examined.
Therefore, the observed deletion should be reclassified as
an interstitial deletion that leaves the subtelomeric part
of the chromosome intact.
Similarly, no abnormalities at the telomeres of chro-
mosome 2 were identified by array-based CGH in patient
13 (46,XX,add[2][q36.2]). Unfortunately, no patientma-
terial was available for additional FISH validation. Chro-
mosomal CGH could, however, be performed with DNA
from the same batch as was used for array-based CGH.
The results of this experiment showed a gain at 8q24
(not shown), suggesting an insertion of chromosome 8
material into the long arm of chromosome 2, leaving the
subtelomeric regions of the derivative chromosome 2
unaffected.
The karyotype of patient 18 indicated an inversion
and duplication of part of the short arm of chromosome
8 (46,XY,dup[8][p23p12]). Array-based CGH results of
both 8pter clones, however, revealed a deletion of the
subtelomeric region of 8p. These results were confirmed
by FISH with both clones present on the array and
indicated that the inversion duplication of the distal part
of 8p indeed coincided with a deletion of the very distal
(subtelomeric) region of 8p, a previously reported cy-
togenetic anomaly (de Die-Smulders et al. 1995; Guo
et al. 1995).
An inversion and duplication was also indicated at the
distal part of the long arm of chromosome 17 in patient
8 (45,XY,der[13;14][q10;q10],dup[17][qterq24.2]).
DNA copy-number analysis by array-based CGH re-
sulted in a remarkable profile (fig. 1B). One 17qter clone
(GS-50C4, with an estimatedmaximumphysical distance
of 100–300 kb from the telomere [Knight et al. 2000])
revealed a copy-number gain, completely in line with the
karyotype. However, the other clone (GS-362K4, with a
maximum physical distance of 90 kb from the telomere
[Knight et al. 2000]) clearly revealed a copy-number loss.
These results were confirmed by FISH and show that the
inversion duplication of the distal part of 17q coincided
with a deletion of the last 100 kb of the subtelomeric
region. These results are reminiscent of those obtained
for patient 18.
Finally, the potential of array-based CGH for the de-
tection of cryptic cytogenetic abnormalities was shown
most clearly in patient 14 (46,XX,der[9]t[9;?][p24;?]).
In this patient, the translocation partner of chromosome
9p could not be identified by routine cytogenetic anal-
ysis. Array-based CGH clearly showed loss of both 9p
subtelomeric clones and, next to that, a copy-number
gain of the 7pter clone (fig. 1C). FISH validation ex-
periments confirmed translocation of the corresponding
7p region to 9pter, thereby refining the cytogenetic di-
agnosis as an unbalanced translocation between chro-
mosomes 7 and 9.
Next to the correct identification of the affected telo-
meric regions in all patients, six clone hybridizations
showed mean intensity ratios (merely) crossing the
thresholds of 0.8 and 1.2 in these 20 experiments. Al-
though no FISH experiments were performed to validate
these observations, we assume that these were false-
positive results, on the basis of the presence of unaltered
profiles for the other clone(s) located in the same sub-
telomeric regions.
To further determine the accuracy and reproducibility
of array-based CGH for the detection of subtelomeric
copy-number gains and losses, we hybridized genomic
DNA from one patient with a deletion of the distal part
of the long arm of chromosome 7 in four different ex-
periments to the telomeric array (patient 10; fig. 1D).
These experiments were performed onto a new batch
of arrays containing whole clone DNAs as well as DOP-
PCR products from all clones, to compare the perform-
ance of array-based CGH on DOP-PCR products with
that of array-based CGH on primary clone DNAs. The
intensity ratios observed for the 7q clone GS-3K23 var-
ied, for total clone DNA, between 0.58 and 0.67 (mean
0.62) and, for the DOP-PCR product, between 0.69 and
0.85 (mean 0.73), which, except for one of the four
DOP-PCR products, is well below the threshold for
copy-number loss of 0.8. Clones mapping to other sub-
telomeric regions showed mean ratios between 0.87 and
1.18 (mean 1 and mean SD 0.05 for the clone DNAs,
as well as for the DOP-PCR products), none of which
was above or below the threshold for copy-number gain
and loss, respectively. The SDs of the DOP-PCR prod-
ucts of two clones, GS-1011-O17 on 2qter and GS-546-
C11 on 19pter, however, crossed the threshold for copy-
number gain due to a false-positive result in one of the
four repeat experiments.
Discussion
We here demonstrate the application of a new array-
based subtelomeric assay, capable of screening all human
subtelomeric regions in a single hybridization reaction.
Telomeric abnormalities were correctly detected in all
patients with previously identified telomeric deletions
and duplications. In addition a refined cytogenetic di-
agnosis was established by array-based CGH in 5 pa-
tients. The mean T/R ratios obtained for single copy
alterations are comparable to measurements performed
by Pinkel et al. (1998) by use of cell populations con-
taining one to five copies of the X chromosome and
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calculations recently reported by Snijders et al. (2001).
Importantly, no false-negative results were obtained in
this study, and the number of presumed false-positive
clone signals was very low (0.4%). With further optim-
ization of this technology, it is to be expected that the
false-positive rate will decrease even further, requiring
only minimal FISH-based validation. At this moment,
however, we strongly suggest for clinical diagnosis to
confirm all positive results by FISH.
Telomere screening by array-based CGH has many
advantages over other methods available for telomere
screening, including microsatellite analysis (Flint et al.
1995; Slavotinek et al. 1999), the Multiprobe T assay
(Knight et al. 1997), primed in situ labeling (Bonifacio
et al. 2001), and the very recently developed M-TEL
assay (Brown et al. 2001) and MAPH-technique (Ar-
mour et al. 2000; Sismani et al. 2001). A total of 77
subtelomeric probes were screened in a single reaction
and required only 500 ng genomic DNA from the pa-
tient. This clone set can easily be extended, to further
increase the sensitivity for detecting genomic imbal-
ances. The use of DNA instead of metaphase spreads
used in FISH-based approaches greatly enhances appli-
cability and (semi)automation of the assay. In addition,
extensive labeling procedures as performed for the M-
TEL assay (Brown et al. 2001) are not required, since
array-based CGH builds upon heavily optimized and
simplified CGH protocols that use only two fluoro-
chromes (Weiss et al. 1999; Lichter et al. 2000). Until
recently, the major drawback of array-based CGH was
the laborious isolation of suitable quantities of DNA
from the target large-insert clones to be spotted on the
arrays. This procedure can now be replaced by a robotic
miniprep procedure in combination withDOP-PCR am-
plification, as we have shown in this study. In the small
test experiment, array-based CGH on DOP-PCR prod-
ucts performed slightly less well than array-based CGH
on whole BAC DNAs, and this will have to be opti-
mized. In addition, alternative PCR-based amplification
procedures have also been developed and will be of help
in preparing high-quality target DNA (Snijders et al.
2001).
Array-based subtelomeric screening is expected to
have a profound impact on the diagnosis and genetic
counseling of patients with mental retardation. Recent
reports in the literature (Knight et al. 1999; Slavotinek
et al. 1999; de Vries et al. 2001) suggest that cryptic
subtelomeric rearrangements may account for 6%–8%
of unexplained mental retardation and congenital
anomalies. Automated detection of subtle deletions and/
or duplications by array-based CGH brings telomere
screening within reach of most diagnostic cytogenetic
laboratories at a reasonable cost.
As a next step, molecular karyotyping by array-based
CGH may be extended to thousands of randomly se-
lected clones, thereby improving the resolution of copy-
number screening from ∼5 Mb (routine karyotyping) to
ultimately as little as 100 kb (30,000 clones evenly
spread over the genome). Currently, 7,600 large-insert
clones have been integrated into the draft sequence of
the human genome (Cheung et al. 2001). Collectively,
they represent ideal targets to be used for array-based
CGH. With these tools in hand, copy-number altera-
tions, as detected by array-based CGH, can be trans-
lated directly to the gene level by use of clone-specific
sequence information present in the public domain. This
will soon allow a whole-genome copy-number screening
at unprecedented resolution in a single reaction and con-
current disease-gene identification.
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